Agree, would be awesome to show benefit of narmafotinib in both gemcitabine and fluorouracil based regimes. At the end of the day whilst folfirinox is preferred, a lot of patients can't tolerate it (or are deemed not up for it in the first place) and end up on gemcitabine/nab-paclitaxel. If we show benefit in both then happy days.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)